USA > " More than 110 million people in the US had health insurance that covered Transgenomic’s cancer tests. They include plans that are part of UnitedHealthcare, Blue Cross/Blue Shield, Aetna, Humana, MultiPlan and the PHCS network, and other major insurers. The company also reported that it expects coverage to increase by more than 50 million lives in 2016, through revisions to existing contracts and expected signings of new contracts with additional insurers.
“We believe that our success in obtaining broad insurance coverage for our cancer tests reflects the fact that by design, our portfolio focuses on actionable genetic mutations that are included in current cancer guidelines and are of practical utility to patients and their oncologists, providing insight into which drugs might be most appropriate for the patient at that point in their treatment,” said Paul Kinnon, President and CEO of Transgenomic. “Since they are based on our unique ICE COLD-PCR™ technology, our tests also work exceptionally well with either blood or tissue samples, enabling their use with almost any cancer patient at all stages of the disease. We are pleased with the breadth of coverage to date and expect to increase insurer coverage in the new year, as we also work to educate doctors and patients about the advantages of our growing menu of cancer tests.”
Last month, Transgenomic announced the launch of its comprehensive Multiplexed ICE COLD-PCR Non-Small Cell Lung Cancer (NSCLC) Analysis panel that covers the key actionable mutations that are relevant to the targeted treatment of NSCLC, one of the most common types of cancer and the leading cause of cancer deaths in the US. It followed the earlier launch of tests for lung cancer and for detection of KRAS and NRAS mutations in colorectal cancer. Additional cancer tests are in development. Transgenomic’s cancer tests are available for clinical diagnostic use through the company’s CLIA laboratory.
DUKE BASKETBALL and NOTRE DAME FOOTBALL
